Female sex is associated with up to 44% increased odds of chronic rhinosinusitis without nasal polyps (CRSsNP), but 37% ...
The FDA has approved Tezspire (tezepelumab-ekko), a biologic therapy by Amgen and AstraZeneca, as an add-on maintenance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback